Drugs / VCL CT02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00373412 | Oct 2006 → Feb 2008 | cytomegalovirus infection | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCL-CT02 | “This is a Phase 1, single-center, randomized, open-label trial of the live, attenuated Towne CMV vaccine administered as a "challenge" to healthy, CMV-seronegative, adult...” NCT00373412 ↗ |
| Modality | Vaccine | “VCL CT02 pDNA vaccine” NCT00373412 ↗ |
| Route | Intramuscular | “VCL-CT02, given by intramuscular route” NCT00373412 ↗ |